GlassScriptPhysician profile
Rex F Largen
NPI 1326036112
$25,683.93
in general payments reported to CMS, 2019-2025
37 companies · $5,885 in 2025
The $5,885 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,783 · 2020: $3,775 · 2021: $2,570 · 2022: $3,620 · 2023: $4,001 · 2024: $4,049 · 2025: $5,885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $1,300 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,355.73 |
| Consulting Fee | $1,300.00 |
| Education | $279.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $4,244.69 | 2019-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $4,080.65 | 2019-2025 | |
| Janssen Biotech, INC. | $2,545.52 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $1,717.65 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $1,566.33 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $1,512.25 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $1,397.55 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $1,109.43 | 2019-2025 | |
| Genzyme Corporation | $1,102.18 | 2021-2025 | |
| Pfizer INC. | $1,075.71 | 2019-2025 | |
| Amgen INC. | $972.07 | 2019-2025 | Otezla, Otezla, Enbrel |
| Incyte Corporation | $764.42 | 2021-2025 | Opzelura, Opzelura |
| E.R. Squibb & Sons, L.L.C. | $686.78 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $556.30 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| Galderma Laboratories, L.P. | $498.02 | 2019-2025 | Nemluvio, Aklief |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $459.91 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $322.38 | 2019-2025 | Siliq, Cabtreo, Arazlo |
| Genentech USA, INC. | $164.47 | 2019-2024 | Erivedge |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.26 | 2022-2025 | Spevigo |
| Almirall LLC | $109.42 | 2019-2024 | Seysara |
| Arcutis Biotherapeutics, INC. | $89.21 | 2023-2024 | Zoryve |
| Celgene Corporation | $88.13 | 2019 | |
| Ani Pharmaceuticals, INC. | $76.10 | 2025 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $72.80 | 2019-2020 | |
| Organon LLC | $52.72 | 2025 | Vtama |
| Botanix Sb INC | $43.12 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $36.57 | 2020 | |
| Sandoz INC. | $27.35 | 2023-2024 | Hyrimoz |
| Mallinckrodt Hospital Products INC. | $26.58 | 2024 | Acthar |
| Dermira, INC. | $26.14 | 2019-2020 | |
| Regeneron Pharmaceuticals, INC. | $21.26 | 2025 | Dupixent |
| Kyowa Kirin, INC. | $20.58 | 2022 | |
| Organogenesis INC. | $20.50 | 2021 | |
| Genentech, INC. | $16.62 | 2023 | Erivedge |
| Promius Pharma LLC | $15.91 | 2019 | |
| Paratek Pharmaceuticals, INC. | $13.88 | 2022 | |
| Biofrontera INC. | $13.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rex Largen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.